BridgeBio
Palo Alto, California, United States · Biotechnology, Health Care, Therapeutics
BridgeBio Oncology Therapeutics (BBOT) has launched with a $200m private financing round, aiming to expedite the development of the company’s precision oncology pipeline and focusing on new cancer treatments.
Key facts
- Headquarters
- Palo Alto, California, United States
- Employees
- 730
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (BBIO)
- Website
- bridgebio.com
- Company page
Recent activity at BridgeBio
- : BridgeBio Pharma Enters Agreement with U.S. Government for Medicine Affordability
- : BridgeBio Pharma, Inc. launches BEYONTTRA™ (acoramidis), a new treatment for transthyretin amyloidosis approved by the European Commission.
- : BridgeBio Pharma, Inc. Publishes Case Study on Portfolio Theory's Role in Biomedical Innovation
- : BridgeBio Oncology Therapeutics (BBOT) raised $200m in a private financing round led by Cormorant Asset Management and Omega Funds to expedite precision oncology pipeline development.
- : BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
BridgeBio funding history
| Date | Round | Amount |
|---|---|---|
| May 2024 | Pre-Seed | $200 |
| Jan 2024 | Venture | $1.3B |
Leadership
- Adora Ndu, Chief Regulatory Officer
- Damian Wilmot, Chief Legal Officer
Verified email and direct lines for BridgeBio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
BridgeBio in the news
- BridgeBio to Participate in September Investor Conferences - Yahoo Finance (Sep 01, 2026)
- BridgeBio Submits NDA for BBP-418 in LGMD2I/R9, Potentially the First Approved Therapy for Any Form of Limb-Girdle Muscular Dystrophy - NeurologyLive (Mar 30, 2026)
- Why BridgeBio Pharma (BBIO) Stock Is Down Today - Quiver Quantitative (Sep 23, 2026)
- Four healthcare conferences will feature BridgeBio management in September, with events in Boston and New York. - Stock Titan (Sep 01, 2026)
- Latham Advises BridgeBio on Preferred Equity Investment - Latham & Watkins LLP (Jul 01, 2026)
- BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis - MarketBeat (Jan 16, 2026)
- BridgeBio Pharma Drops Development of Congenital Adrenal Hyperplasia Gene Therapy BBP-631 - CGTLive® (Sep 16, 2024)
- BridgeBio Pops on Late-Stage Limb-Girdle Muscular Dystrophy Data - BioSpace (Oct 27, 2025)
Companies similar to BridgeBio
- Ouro Medicines · Biotechnology, Health Care, Therapeutics
- Apellis Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Cytokinetics · Biotechnology, Health Care, Therapeutics
- Adaptive Biotechnologies Corporation · Biotechnology, Health Care, Therapeutics
- Iovance Biotherapeutics · Biotechnology, Health Care, Therapeutics
About BridgeBio: questions and answers
What does BridgeBio do?
BridgeBio Oncology Therapeutics (BBOT) has launched with a $200m private financing round, aiming to expedite the development of the company’s precision oncology pipeline and focusing on new cancer treatments.
Where is BridgeBio headquartered?
BridgeBio is headquartered in Palo Alto, California, United States.
How many employees does BridgeBio have?
BridgeBio has about 730 employees.
Has BridgeBio raised funding?
Yes. Fundz has recorded 2 funding events for BridgeBio. The most recent, Pre-Seed of $200, was in May 2024.
What is the latest news on BridgeBio?
On Aug 31, 2026, BridgeBio Pharma Enters Agreement with U.S. Government for Medicine Affordability
Is BridgeBio a public company?
Yes. BridgeBio is publicly traded under the ticker BBIO.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy